(Nuqui)

"You have cancer."

Sadly, about 40 percent of us will hear those three words within our lifetime,
and half will not survive.
This means that two out of five of your closest friends and relatives
will be diagnosed with some form of cancer,
and one will die.

Beyond the physical hardships,

roughly one-third of cancer survivors here in the Philippines
will go into debt from treatment.
And they're at least two and a half times more likely to declare bankruptcy
than those without cancer.
This disease is pervasive.
It's emotionally draining
and, for many,
financially destructive.
But a cancer diagnosis doesn't have to be a death sentence.
Finding cancer early,
closer its genesis,
is one of the critical factors to improving treatment options,
reducing its emotional impact
and minimizing financial burdens.
Most importantly,
finding cancer early --
greatly enhances your odds of survival.
If we just look at the case of breast cancer for example,
we find that those who are diagnosed and treated at stage one
have a five-year survival rate of nearly 100 percent --
odds that decrease to just 22 percent if treated at stage four.
And similar trends are found for colorectal and ovarian cancer.
Now, we're all aware that an early diagnosis that is accurate
is critical for survival.
The problem is that many cancer diagnostic tools are invasive,
costly,
often inaccurate
and they can take an agonizing amount of time to get the results back.
Still worse, when it comes to some forms of cancer,
such as ovarian, liver or pancreatic cancer,
good screening methods simply don't exist,
meaning that often people wait until physical symptoms surface,
which are themselves already indicators of late-stage progression.

Like a tornado strike in an area without an early warning system,

there is no alarm to warn,
for the danger is already at your doorstep
when your odds of survival are greatly reduced.
Having the convenience and accessibility of regular screening options
that are affordable, noninvasive and could provide results much sooner,
would provide us with a formidable weapon in the fight against cancer.
An early warning would allow us to get out ahead of the disease
instead of merely following in its relentless wake.
(Aying)

And this is exactly what researcher Joshua Smith and his team has been doing.
Researcher Joshua Smith is developing a nanobiotechnology "cancer alarm"
that scans for traces of disease in the form of
special biomarkers called exosomes.
For the past five years, he's been developing technologies
that could ultimately aid clinicians
with rapid, early-stage cancer diagnostics.
And he's been fueled by a deep scientific curiosity,
and a passion to change these statistics.
in the year 2016 however,
this fight became much more personal
when his wife was diagnosed with breast cancer.
It was an experience that added a strong and unexpected emotional dimension
to his efforts.
He knows firsthand how life-altering treatment can be,
and he's keenly aware of the emotional havoc
that cancer can wreak on a family.
Because they found it early during a routine mammogram,
they were able to focus primarily on treatment options
for the localized tumor,
reaffirming to them how important an early diagnosis is.
Unlike other forms of cancer,
mammograms do offer an early-stage screening option for breast cancer.
Still, not everyone has this done,
or they may develop breast cancer
before the middle age recommendation for having a mammogram.
So, there's still a lot of room for improvement,
even for cancers that do have screening options,
and, of course, considerable benefits for those that don't.
A key challenge then for cancer researchers
is to develop methods
that make regular screening for many types of cancers
much more accessible.
Imagine a scenario where during your regular checkup,
your doctor can take a simple, noninvasive urine sample,
or another liquid biopsy,
and present you with the results before you even leave the doctor's office.
Such a technology could dramatically reduce the number of people
who slip through the net of an early-stage cancer diagnosis.
Joshua Smith's research team of engineers and biochemists
is working on exactly this challenge.
They're working on ways to frequently activate an early-stage cancer alarm
by enabling regular screenings that would start when a person is healthy
so that action could be taken to stop cancer the moment it emerges,
and before it can progress beyond its infancy.
The silver bullet in this case are tiny vesicles,
little escape pods regularly shed by cells called exosomes.
Exosomes are important biomarkers
that provide an early-warning system for the development of cancer.
And because they're abundantly present in just about every bodily fluid,
including blood, urine and saliva,
they're extremely attractive for noninvasive liquid biopsies.
There's just one problem.
An automated system for rapidly sorting these important biomarkers
is not currently available.
they've created a technology that they call Nano-DLD
that is capable of precisely this:
automated exosome isolation
to aid rapid cancer diagnostics.

(De Guzman)

Exosomes are the newest early-warning weapon, if you will,

to emerge on the liquid biopsy front.
And they're really, really small.
They measure just 30 to 150 nanometers in diameter.
This is so tiny
that you could fit about a million of them into a single red blood cell.
That's roughly the difference between a golf ball
and a fine grain piece of sand.
Once thought to be little bins for unwanted cellular waste,
it has been found that cells actually communicate
by producing and absorbing these exosomes
which contain surface receptors,
proteins and other genetic material collected from their cell of origin.
When absorbed by a neighboring cell,
exosomes release their contents into the receiving cell,
and can set in motion fundamental changes in gene expression --
some good,
and this is where cancer comes in,
some bad.
Because they are clothed in the material of the mother cell,
and contain a sample of its environment,
they provide a genetic snapshot of that cell's health and its origin.
All of these qualities make exosomes invaluable messengers
that potentially allow physicians
to eavesdrop on your health at the cellular level.
To catch cancer early, however,
you have to frequently intercept these messages
to determine when cancer-causing troublemakers within your body
decide to start staging a coup,
which is why regular screening being so critical
and why we're developing technologies to make this possible.
While the first exosome-based diagnostics emerged on the market in 2017,
they are not yet part of mainstream healthcare options.
In addition to their recent emergence,
another factor that's limiting their widespread adoption
is that currently, no automated exosome isolation system exists
to make regular screening economically accessible.
The current gold standard for exosome isolation
includes ultracentrifugation,
a process requiring expensive laboratory equipment,
a trained lab tech
and about 30 hours of time to process a sample.
They've come up with a different approach for achieving automated exosome isolation
from a sample such as urine.
They use a chip-based, continuous flow separation technique
called deterministic lateral displacement.
And they have done with it
what the semiconductor industry has done so successfully for the past 50 years.
They shrunk the dimensions of this technology
from the micron scale to the true nanoscale.
So how does it work?
(Sarusal)

In a nutshell,
a set of tiny pillars separated by nanoscopic gaps
are arranged in such a way
that the system divides the fluid into streamlines,
with the larger cancer-related nanoparticles being separated
through a process of redirection from the smaller, healthier ones,
which can in contrast
move around the pillars in a zigzag-type motion
in the direction of fluid flow.
The net result is a complete separation of these two particle populations.
You can visualize this separation process

similar to traffic on a highway that separates into two roads,

with one road going into a low-clearance tunnel under a mountain,
and the other road going around it.
Here, smaller cars can go through the tunnel
while larger trucks, carrying potentially hazardous material,
are forced to take the detour route.
Traffic is effectively separated by size and contents
without impeding its flow.
And this is exactly how our system works on a much, much smaller scale.
The idea here is that the separation process for screening
could be as simple as processing a sample of urine, blood or saliva,
which is a near-term possibility within the next few years.
Ultimately, it could be used to isolate and detect target exosomes
associated with a particular type of cancer,
sensing and reporting their presence within minutes.
This would make rapid diagnostics virtually painless.
Broadly speaking,
the ability to separate and enrich biomarkers
with nanoscale precision in an automated way,
opens the door to better understanding diseases such as cancer,
with applications ranging from sample preparation to diagnostics,
and from drug resistance monitoring to therapeutics.

(Quindiagan)
Even before Joshua Smith's wife's bout with cancer,
it was a dream of his to facilitate the automation of this process --
to make regular screening more accessible,

similar to the way Henry Ford made the automobile accessible

to the general population
through development of the assembly line.
Automation is the key to accessibility.
And in the spirit of the Hoover dream,
"a chicken in every pot and a car in every garage,"
we're developing a technology
that could ultimately place an early-warning cancer detection system
in every home.
This would allow every man, woman and child
the opportunity to be regularly tested while they're still healthy,
catching cancer when it first emerges.
It is our hope and dream
to help people around the world avoid the high costs --
physical, financial and emotional --
faced by today's cancer patients,
hardships that we're all well acquainted with.
We are also happy to report that because they caught Joshua Smith's wife's cancer early,
her treatment was successful,
and she is now, thankfully, cancer-free.
It is an outcome that we would like to see for everyone with a cancer diagnosis.
With the work of Joshua Smith and his team has already done
on separation of nanoscale biomarkers
for rapid, early-stage cancer diagnostics,
We are optimistic that within the next decade,
this type of technology will be available,
helping protect our friends, our family and future generations.
Even if we are so unlucky as to be diagnosed with cancer,
that early-stage alarm will provide a strong beacon of hope.
Thank you.